Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversibl… Read more
Enliven Therapeutics Inc. (ELVN) - Total Liabilities
Latest total liabilities as of December 2025: $16.68 Million USD
Based on the latest financial reports, Enliven Therapeutics Inc. (ELVN) has total liabilities worth $16.68 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Enliven Therapeutics Inc. - Total Liabilities Trend (2017–2025)
This chart illustrates how Enliven Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Enliven Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Enliven Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Visionox Technology Inc
SHE:002387
|
China | CN¥31.60 Billion |
|
Mabwell (Shanghai) Bioscience Co. Ltd. A
SHG:688062
|
China | CN¥3.58 Billion |
|
Hanma Technology Group Co Ltd
SHG:600375
|
China | CN¥4.94 Billion |
|
Upbound Group Inc.
NASDAQ:UPBD
|
USA | $2.52 Billion |
|
CVS Group plc
PINK:CVSGF
|
USA | $434.80 Million |
|
Karoon Energy Ltd
PINK:KRNGY
|
USA | $741.10 Million |
|
MLS Co Ltd
SHE:002745
|
China | CN¥11.18 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Enliven Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enliven Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enliven Therapeutics Inc. (2017–2025)
The table below shows the annual total liabilities of Enliven Therapeutics Inc. from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $16.68 Million | +4.78% |
| 2024-12-31 | $15.91 Million | -38.70% |
| 2023-12-31 | $25.96 Million | -83.79% |
| 2022-12-31 | $160.12 Million | +2376.00% |
| 2021-12-31 | $6.47 Million | +0.94% |
| 2020-12-31 | $6.41 Million | +46.21% |
| 2019-12-31 | $4.38 Million | +139.19% |
| 2018-12-31 | $1.83 Million | +23.28% |
| 2017-12-31 | $1.49 Million | -- |